TrialDrugs in R&D2017

A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m

Alejandro Muggeri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.